Skip to main content
. Author manuscript; available in PMC: 2013 Jul 5.
Published in final edited form as: Int J Gynecol Cancer. 2010 Dec;20(9):1440–1447.

FIGURE 2.

FIGURE 2

Effect of low doses of IL-2 in combination with MT201 (5 μg/mL) on ADCC against 2 primary cervical cancer cell lines overexpressing EpCAM (ie, CVX-2 and CVX-7: effectors to target ratio 25:1). Peripheral blood lymphocytes from healthy donors were incubated for 4 hours in the presence of 100 IU/mL of IL-2. MT201-mediated ADCC was significantly increased in the presence of low doses of IL-2. No significant increase in cytotoxicity was detected after a 4-hour IL-2 treatment in the absence of MT201 or in the presence of the rituximab isotype control mAb. Gray bars, no IL-2; black bars, IL-2.